drugset
drugset / Trial / NCT04906473

Safety,Tolerability, Pharmacokinetic,Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid Tumors

NCT04906473 ↗

Phase 1 Unknown 109 enrolled Kunming Pharmaceuticals, Inc.
NaSequentialOpen-labelTreatment

Summary

to assess the safety,tolerability, pharmacokinetic,pharmacodynamics and efficacy of KY100001 in patients with advanced solid tumors

Timeline

Start
2021-07-31
Primary completion
2022-12-31
Completion
2023-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject KY100001 Unknown 100 mg Oral
Subject KY100001 Unknown 200 mg Oral
Subject KY100001 Unknown 350 mg Oral
Subject KY100001 Unknown 550 mg Oral
Subject KY100001 Unknown 750 mg Oral

Indications

neoplasm